Abstract: OBJECTIVE To analyze and evaluate the clinical efficacy and safety of tigecycline in the treatment of the infections caused by multidrug or extensively drug resistant Acinetobacter baumannii(MDRAB/XDRAB), so as to provide additional evidence for its clinical treatment. METHODS A total of 71 hospitalized patients in Xijing Hospital from Jan. 2014 to Mar. 2016 who used tigecycline for the treatment of MDRAB or XDRAB infections were collected. Medication regimen, changes of temperature(T),white blood cells (WBC),C-reactive protein (CRP),and procalcitonin (PCT) before and after the treatment, clinical effective rates, microbiological eradication rate,30-day mortality and the incidence of adverse reactions were retrospectively analyzed. RESULTS Among 71 hospitalized patients, the clinical efficacy rate was 71.83%, the microbiological eradication rate was 35.21%, the 30-day mortality was 14.08%, and the incidence of adverse reactions was 14.08%. After treated with tigecycline, temperature and WBC were decreased significantly(P<0.05). In comparison with monotherapy, tigecycline combination therapy had a significantly higher mortality, and combination with sulbactam had a significantly higher microbiological eradication rate, with significant differences(P<0.05). CONCLUSION Tigecycline can achieve good therapeutic effect and safety in the treatment of MDRAB or XDRAB infections, and can be considered as an alternative therapy regimen after the failure of conventional therapy.